On 26 March 2026, Magle Chemoswed Holding AB (publ) (the "Company") announced that it had initiated a written procedure in relation to its senior secured bonds 2025/2028 with ISIN SE0025197403 (the "Bonds"), to request the holders of the Bonds vote in favor of, among other things, amending the terms and conditions of the Bonds to implement the amended capital structure of the Company. The full details of the proposal are set out in the notice of written procedure.

A sufficient number of bondholders participated in the written procedure and the requisite majority voted in favour of the proposals. The Company is therefore pleased to announce the successful completion of the written procedure.

The Company will continue with the implementation of the contemplated amendments and waivers as set out in the notice of written procedure in accordance with the below time plan.

Record date for holders of the Bonds to receive consent fee shares.29 April 2026Announcement of preliminary outcome of the rights issue announced by the Company on 25 March 2026 (the “Rights Issue”).30 April 2026Conditions for the effectiveness of the approval of the proposals set out in the written procedure are fulfilled.8 May 2026Board of directors of the Company resolves on the issuance of the consent fee shares.11 May 2026 (target date)Delivery of the consent fee shares to the nominees.13 May 2026 (target date)

For additional information, please contact:Aaron Wong, CEOMagle Chemoswed Holding AB (publ)Tel.: +46 733 44 01 52Email: aaron.wong@maglegroup.com

Contacts Aaron

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.comRedeye Nordic Growth AB is the company's Certified Adviser.

Attachments

Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028